Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Did you mean category antidepressive agent an group approved?
Displaying drugs 301 - 325 of 10408 in total

Bezlotoxumab

Bezlotoxumab is a fully humanized ImmunoglobulinG1 (IgG1) kappa monoclonal antibody that binds to Clostridium difficile toxin B and neutralizes its effects. First approved by the FDA on October 21, 2016, bezlotoxumab is used to reduce the recurrence of C. difficile infection. On November 22, 2016, the Committee for Medicinal Products...
Approved
Investigational
Matched Description: … [L46976] First approved by the FDA on October 21, 2016,[A260106] bezlotoxumab is used to reduce the recurrence …

Melphalan

Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard.[A261150, A261155] Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-conditioning before hematopoietic stem...
Approved
Matched Description: … [L40928] It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group …
Matched Categories: … Antineoplastic Agents ... Myelosuppressive Agents ... Immunosuppressive Agents ... Antineoplastic Agents, Alkylating ... Antineoplastic and Immunomodulating Agents …

Chloroprocaine

Chloroprocaine is an ester local anesthetic commonly available in its salt form, chloroprocaine hydrochloride. Similar to other local anesthetics, it increases the threshold for electrical excitation in nerves by slowing the propagation of the nerve impulse and reducing the rate of rise of the action potential. The pharmacological profile of...
Approved
Investigational
Matched Description: … [A252952,L43382] Topical chloroprocaine for ophthalmic use was approved by the FDA in September 2022 ... Chloroprocaine is an ester local anesthetic commonly available in its salt form, chloroprocaine hydrochloride ... [A252952] Chloroprocaine can be given as an injection, and is available in formulations with and without …
Matched Categories: … Sensory System Agents ... Central Nervous System Agents ... Peripheral Nervous System Agents …

N-acetyltyrosine

N-acetyltyrosine, also referred to as N-acetyl-L-tyrosine, is used in place of as a tyrosine precursor. DB00135 is a non-essential amino acid with a polar side group. N-acetyltyrosine is administered as parenteral nutrition or intravenous infusion due to its enhanced solubility compared to tyrosine . It is typically administered as a...
Approved
Matched Description: … [DB00135] is a non-essential amino acid with a polar side group. …

Amiloxate

Amiloxate is an EMA-approved chemical UV-filter found in over-the-counter sunscreen products at concentrations up to 10%m . It is often referred to as isoamyl 4-methoxycinnamate or isoamyl p-methoxycinnamate. Amiloxate is a cinnamic acid derivative with an anti-inflammatory activity .
Approved
Matched Description: … Amiloxate is an EMA-approved chemical UV-filter found in over-the-counter sunscreen products at concentrations ... Amiloxate is a cinnamic acid derivative with an anti-inflammatory activity [A32916]. …
Matched Categories: … Sunscreen Agents …

Triflupromazine

A phenothiazine used as an antipsychotic agent and as an antiemetic.
Approved
Vet approved
Matched Description: … A phenothiazine used as an antipsychotic agent and as an antiemetic. …
Matched Categories: … Antidepressive Agents ... Autonomic Agents ... Dopamine Agents ... Antipsychotic Agents ... Anticholinergic Agents …

Bepridil

A long-acting, non selective, calcium channel blocker with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist. It is no longer marketed in the United States, as it has been implicated in causing...
Approved
Withdrawn
Matched Categories: … Antiarrhythmic agents ... Antihypertensive Agents ... Cardiovascular Agents ... Hypotensive Agents ... Agents causing hyperkalemia …

Lucinactant

Lucinactant is a new synthetic peptide-containing surfactant for intratracheal use. It contains sinapultide, a novel, hydrophobic, 21-amino acid peptide (leucine and lysine repeating units, KL4 peptide) designed to mimic human surfactant protein-B (SB-P). More specifically, it mimics the C-terminal amphipathic helical domain of this protein. It also consists of phospholipids...
Approved
Investigational
Matched Description: … FDA approved on March 6, 2012. …
Matched Categories: … Bradycardia-Causing Agents …

Solriamfetol

Solriamfetol marketed under the brand name Sunosi by Jazz Pharmaceuticals in the United States is a dopamine and norepinephrine reuptake inhibitor (DNRI) indicated in treating daytime sleepiness associated with narcolepsy or obstructive sleep apnea[FDA Label]. Solriamfetol was given FDA approval in 2019[FDA Label].
Approved
Matched Categories: … Antidepressive Agents ... Adrenergic Agents ... Dopamine Agents ... Agents producing tachycardia ... Central Nervous System Agents …

Propiomazine

Propiomazine, an atypical antipsychotic agent, is used to treat both negative and positive symptoms of schizophrenia, acute mania with bipolar disorder, agitation, and psychotic symptoms in dementia. Future uses may include the treatment of obsessive-compulsive disorder and severe behavioral disorders in autism. Structurally and pharmacologically similar to clozapine, propiomazine binds...
Approved
Matched Description: … Propiomazine, an atypical antipsychotic agent, is used to treat both negative and positive symptoms of …
Matched Categories: … Antidepressive Agents ... Serotonin Agents ... Anticholinergic Agents ... Agents producing tachycardia ... Agents that produce hypertension …

Satralizumab

Satralizumab is a recombinant humanized monoclonal antibody targeted against human interleukin-6 (IL-6) receptors, similar to tocilizumab, which is produced in Chinese hamster ovary cells and based on an IgG2 framework. Satralizumab is used in the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune inflammatory disorder of the central...
Approved
Matched Description: … [A218551] It received subsequent approvals in Switzerland and Japan,[A218551] and was approved for use ... Satralizumab was first approved for use in Canada in June 2020 for the treatment of AQP4 antibody-positive ... receptors, similar to [tocilizumab], which is produced in Chinese hamster ovary cells and based on an …
Matched Categories: … Immunosuppressive Agents ... Antineoplastic and Immunomodulating Agents …

Sulfasalazine

Sulfasalazine is an anti-inflammatory drug structurally related to salicylates and other non-steroidal anti-inflammatory drugs. It is indicated for managing inflammatory diseases such as ulcerative colitis and rheumatoid arthritis (RA).[L39065, A255582] Metabolized by intestinal bacteria, sulfasalazine is broken down into mesalazine and sulfapyridine, 2 compounds that carry out the main pharmacological...
Approved
Matched Description: … Sulfasalazine is an anti-inflammatory drug structurally related to salicylates and other non-steroidal ... [A255582] Although sulfasalazine is only approved by the FDA for ulcerative colitis, research have …
Matched Categories: … Nephrotoxic agents ... Agents causing hyperkalemia ... Antirheumatic Agents ... Anti-Inflammatory Agents ... Gastrointestinal Agents …

Lidoflazine

Approved
Experimental
Matched Categories: … Antiarrhythmic agents ... Cardiovascular Agents ... Agents causing hyperkalemia ... Vasodilating Agents ... Bradycardia-Causing Agents …

Formoterol

Formoterol is an inhaled beta2-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers....
Approved
Investigational
Matched Description: … first approved for use in the United States in 2001. ... Formoterol is an inhaled beta2-agonist used in the management of COPD and asthma that was …
Matched Categories: … Adrenergic Agents ... Autonomic Agents ... Anti-Asthmatic Agents ... Bronchodilator Agents ... QTc Prolonging Agents …

Diroximel fumarate

Multiple Sclerosis (MS) is a chronic, debilitating neurological disease that can lead to profound cognitive and physical symptoms, severely affecting quality of life. It is the main cause of neurological disability not caused by trauma in the young adult population of both North America and Europe. Relapsing-remitting forms of MS...
Approved
Investigational
Matched Description: … Diroximel fumarate was formulated by Alkermes in collaboration with Biogen, and was approved by the FDA …
Matched Categories: … Hepatotoxic Agents ... Immunosuppressive Agents ... Antineoplastic and Immunomodulating Agents …

Aclidinium

Aclidinium is an anticholinergic for the long-term management of chronic obstructive pulmonary disease (COPD). It has a much higher propensity to bind to muscarinic receptors than nicotinic receptors. FDA approved on July 24, 2012.
Approved
Matched Description: … FDA approved on July 24, 2012. ... Aclidinium is an anticholinergic for the long-term management of chronic obstructive pulmonary disease …
Matched Categories: … Anticholinergic Agents ... Agents producing tachycardia ... Agents to Treat Airway Disease …

Lemborexant

Lemborexant is a novel dual orexin receptor antagonist used in the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance. Recent research in the field of sleep disorders has revealed that insomnia is likely driven not by the inability of the brain to "switch on" sleep-related circuits,...
Approved
Investigational
Matched Description: … is likely driven not by the inability of the brain to "switch on" sleep-related circuits, but rather an ... [A189006] This novel mechanism of action offers potential advantages over classic hypnotic agents, including …
Matched Categories: … Central Nervous System Agents ... Neurotransmitter Agents …

Vernakalant

Vernakalant was developed by Cardiome Pharma as as an antiarrhythmic drug intended for rapid conversion of atrial fibrillation to sinus rhythm. It acts as an atypical class III antiarrhythmic drug that potentiates its effect in higher heart rates. Intravenous formulation was approved in Europe in September 2010 as Brinavess and...
Approved
Investigational
Matched Description: … Intravenous formulation was approved in Europe in September 2010 as Brinavess and in Canada in April ... It is an investigational drug under regulatory review by FDA. ... Vernakalant was developed by Cardiome Pharma as as an antiarrhythmic drug intended for rapid conversion …
Matched Categories: … Antiarrhythmic agents ... QTc Prolonging Agents ... Potential QTc-Prolonging Agents …

Oxycodone

Oxycodone is a semisynthetic opioid analgesic derived from thebaine in Germany in 1917. It is currently indicated as an immediate release product for moderate to severe pain and as an extended release product for chronic moderate to severe pain requiring continuous opioid analgesics for an extended period.[Label] The first oxycodone...
Approved
Illicit
Investigational
Matched Description: … [Label] The first oxycodone containing product, Percodan, was approved by the FDA on April 12, 1950. ... for an extended period. ... [A178696] It is currently indicated as an immediate release product for moderate to severe pain and as …
Matched Categories: … Central Nervous System Agents ... Sensory System Agents ... Peripheral Nervous System Agents …

Dabrafenib

Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib),...
Approved
Investigational
Matched Description: … to treat anaplastic thyroid cancer caused by an abnormal BRAF V600E gene. ... It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. ... [L41955] In May 2018, Tafinlar (dabrafenib), in combination with Mekinist ([DB08911]), was approved …
Matched Categories: … Antineoplastic Agents ... QTc Prolonging Agents ... Photosensitizing Agents ... Hyperglycemia-Associated Agents ... Antineoplastic and Immunomodulating Agents …

Flucloxacillin

Antibiotic analog of cloxacillin.
Approved
Investigational
Matched Categories: … Anti-Bacterial Agents ... Anti-Infective Agents …

Strontium chloride

Strontium chloride (SrCl2) is a salt of strontium and chloride. SrCl2 is useful in reducing tooth sensitivity by forming a barrier over microscopic tubules in the dentin containing nerve endings that have become exposed by gum recession [A33167, A33168]. This kind of barrier protection for tooth hypersensitivity has, however, been...
Approved
Matched Description: … however, been superseded by other toothpaste formulations and ingredients designed to be nerve calming agents …

Olanzapine

Olanzapine is a thienobenzodiazepine classified as an atypical or second-generation antipsychotic agent. The second-generation antipsychotics were introduced in the 90s and quickly gained traction due to their impressive efficacy, reduced risk for extrapyramidal side effects and reduced susceptibility to drug-drug interactions. Olanzapine very closely resembles clozapine and only differs by...
Approved
Investigational
Matched Description: … Olanzapine is a thienobenzodiazepine classified as an atypical or second-generation antipsychotic agent ... [T554] It was discovered by scientists at Eli Lilly and approved to be marketed in the US in 1996. …
Matched Categories: … Antidepressive Agents ... Autonomic Agents ... Antipsychotic Agents ... Anticholinergic Agents ... Serotonin Agents …
Matched Products: … Truemed Group LLC …

Linezolid

Linezolid is a synthetic antibiotic which is used for the treatment of infections caused by aerobic Gram-positive bacteria. Its effects are bacteriostatic against both enterococci and staphylococci and bactericidal against most isolates of streptococci. Linezolid exerts its antibacterial activity by inhibiting the initiation of bacterial protein synthesis - more specifically,...
Approved
Investigational
Matched Description: … Linezolid was initially approved in 2000 and was the first member of the oxazolidinone antibiotic class ... [A233425] A second member of this class, [tedizolid], was approved by the FDA in 2014 and is considered …
Matched Categories: … Antidepressive Agents ... Serotonin Agents ... Anti-Bacterial Agents ... Anti-Infective Agents ... Myelosuppressive Agents …

Vemurafenib

Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann...
Approved
Matched Categories: … Antineoplastic Agents ... QTc Prolonging Agents ... Photosensitizing Agents ... Antineoplastic and Immunomodulating Agents ... Highest Risk QTc-Prolonging Agents …
Displaying drugs 301 - 325 of 10408 in total